CO2018010880A2 - Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales - Google Patents

Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales

Info

Publication number
CO2018010880A2
CO2018010880A2 CONC2018/0010880A CO2018010880A CO2018010880A2 CO 2018010880 A2 CO2018010880 A2 CO 2018010880A2 CO 2018010880 A CO2018010880 A CO 2018010880A CO 2018010880 A2 CO2018010880 A2 CO 2018010880A2
Authority
CO
Colombia
Prior art keywords
treatment
compound
cxcr
inhibitors
crystal arthropathy
Prior art date
Application number
CONC2018/0010880A
Other languages
English (en)
Inventor
Payal Nanavati
Jeffrey Miner
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of CO2018010880A2 publication Critical patent/CO2018010880A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El N-(2-((2,3-difluorobencil)tio)-6-(((2R,3S)-3,4-dihidroxibutan-2-il)oxi)pirimidin-4-il)azetidin-1-sulfonamida (compuesto 3) y N-(6-(((2R,3S)-3,4-dihidroxi butan-2-il)oxi)-2-((4-fluoro bencil)tio)pirimidin-4-il)-3-metilazetidin-1-sulfonamida (compuesto 4) son moduladores de quimiocina conocidos y por lo tanto son útiles en el tratamiento de enfermedades/afecciones en las cuales es benéfica la modulación de la actividad del receptor de quimiocina. En particular, se proporcionan en la presente compuesto y métodos para el tratamiento y prevención de la gota. Compuesto 3 Compuesto 4
CONC2018/0010880A 2016-03-11 2018-10-10 Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales CO2018010880A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662307348P 2016-03-11 2016-03-11
PCT/US2017/021570 WO2017156270A1 (en) 2016-03-11 2017-03-09 Cxcr-2 inhibitors for treating crystal arthropathy disorders

Publications (1)

Publication Number Publication Date
CO2018010880A2 true CO2018010880A2 (es) 2018-10-22

Family

ID=59789863

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0010880A CO2018010880A2 (es) 2016-03-11 2018-10-10 Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales

Country Status (10)

Country Link
US (1) US10772886B2 (es)
EP (1) EP3426253A4 (es)
JP (2) JP6883917B2 (es)
CN (2) CN113893252A (es)
AU (1) AU2017231832B2 (es)
BR (1) BR112018068393A2 (es)
CA (1) CA3017345A1 (es)
CO (1) CO2018010880A2 (es)
MX (1) MX2018010946A (es)
WO (1) WO2017156270A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10772886B2 (en) 2016-03-11 2020-09-15 Ardea Biosciences, Inc. CXCR-2 inhibitors for treating crystal arthropathy disorders
EP3681861A4 (en) * 2017-09-12 2021-06-09 Ardea Biosciences, Inc. CXCR-2 INHIBITORS FOR THE TREATMENT OF DISORDERS
EP3738956B1 (en) 2018-01-11 2023-03-01 Shenzhen Optimum Biological Technology Co., Ltd Cxcr2 antagonist
EP3998256A4 (en) * 2019-07-11 2023-07-19 Shenzhen Optimum Biological Technology Co., Ltd CRYSTALLINE FORM OF CXCR2 ANTAGONIST AND ITS USE
KR102260478B1 (ko) * 2019-08-19 2021-06-02 연세대학교 산학협력단 일나트륨 요소화물 결정 용해용 조성물
WO2021247499A1 (en) * 2020-06-05 2021-12-09 Aristea Therapeutics, Inc. Use of a combination of colchicine and a cxcr-2 inhibitor for the treatment or prevention of familial mediterranean fever (fmf) and flare-ups thereof
WO2022162021A1 (en) * 2021-01-27 2022-08-04 Astrazeneca Ab Verinurad compositions and methods of use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
WO2009039091A1 (en) 2007-09-21 2009-03-26 Smithkline Beecham Corporation Method of treatment
DE602005022986D1 (de) 2004-01-30 2010-09-30 Schering Corp Kristalline polymorphe eines cxc-chemokinrezeptorliganden
RU2408587C2 (ru) 2004-08-24 2011-01-10 Астразенека Аб Производные пиримидинсульфонамида в качестве модуляторов рецепторов хемокинов
RU2009131454A (ru) * 2007-01-19 2011-02-27 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
US20090093548A1 (en) 2007-10-05 2009-04-09 Mutual Pharmaceutical Company, Inc Colchine compositions and methods
CA2706883A1 (en) 2007-12-04 2009-06-11 Schering Corporation Methods of treating copd
CA2717071A1 (en) 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
RU2011101661A (ru) 2008-07-16 2012-08-27 Астразенека Аб (Se) Пиримидилсульфонамидное производное и его применение для лечения хемокин-опосредованных заболеваний
MX2011003328A (es) 2008-10-06 2011-06-20 Carolus Therapeutics Inc Metodos para tratar inflamacion.
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2010056399A1 (en) 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
WO2010065491A2 (en) 2008-12-01 2010-06-10 Carolus Therapeutics, Inc. Methods of treating inflammatory disorders
WO2010071865A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
DK2421901T3 (en) 2009-04-24 2016-01-11 Tissue Tech Inc Compositions comprising HC-HA complex, and methods of use thereof
MX2012003514A (es) 2009-09-23 2012-04-19 Carolus Therapeutics Inc Metodos para tratamiento de inflamaciones.
WO2011116245A2 (en) 2010-03-19 2011-09-22 Carolus Therapeutics, Inc. Methods of treating inflammation
CA2804162A1 (en) 2010-07-13 2012-01-19 Astrazeneca Ab New crystalline forms of n-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1r,2s)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl}-1-azetidinesulfonamide
EP2608672B1 (en) * 2010-08-23 2020-12-16 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
SG10201605619XA (en) * 2011-07-12 2016-08-30 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
CN114652816A (zh) 2012-07-11 2022-06-24 组织技术公司 含有hc-ha/ptx3复合物的组合物及其使用方法
US20170320954A1 (en) 2014-11-17 2017-11-09 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
US10772886B2 (en) 2016-03-11 2020-09-15 Ardea Biosciences, Inc. CXCR-2 inhibitors for treating crystal arthropathy disorders
US20180221312A1 (en) 2016-03-11 2018-08-09 Ardea Biosciences, Inc. Cxcr-2 inhibitors for treating disorders
EP3681861A4 (en) 2017-09-12 2021-06-09 Ardea Biosciences, Inc. CXCR-2 INHIBITORS FOR THE TREATMENT OF DISORDERS

Also Published As

Publication number Publication date
CA3017345A1 (en) 2017-09-14
JP7126014B2 (ja) 2022-08-25
EP3426253A1 (en) 2019-01-16
MX2018010946A (es) 2019-05-23
JP2021121600A (ja) 2021-08-26
AU2017231832A1 (en) 2018-10-04
CN109152780B (zh) 2021-10-01
JP2019507791A (ja) 2019-03-22
US10772886B2 (en) 2020-09-15
BR112018068393A2 (pt) 2019-01-15
AU2017231832B2 (en) 2021-11-11
WO2017156270A1 (en) 2017-09-14
JP6883917B2 (ja) 2021-06-09
CN109152780A (zh) 2019-01-04
CN113893252A (zh) 2022-01-07
EP3426253A4 (en) 2019-11-06
US20180235964A1 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
CO2018010880A2 (es) Inhibidores de cxcr-2 para tratamiento de trastornos de artropatía por cristales
CO2020003061A2 (es) Inhibidores de cxcr-2 para tratar trastornos
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
ECSP22051489A (es) Compuestos inhibidores de metaloenzimas
EA202090019A1 (ru) Спироциклические индолины в качестве модуляторов il-17
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
CY1124328T1 (el) Δραστικος και αποτελεσματικος ελεγχος tων φωσφορικων ορου για τον βελτιστο σχηματισμο των οστων
EA201790806A1 (ru) Иммунорегулирующие средства
PE20151594A1 (es) Inhibidores de indolamina 2-3 dioxigenasa
EA201992083A1 (ru) Модуляторы соматостатина и их применения
CL2020002719A1 (es) Moduladores de nlrp3
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
BR112018001292A2 (pt) métodos para melhor liberação de agentes ativos a tumores
CO2020000227A2 (es) Moduladores de nlrp3
CL2020002573A1 (es) Inhibidores atf6 y sus usos.
CL2021003257A1 (es) Pirazolo-piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b.
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
ECSP19026702A (es) Compuestos novedosos para el tratamiento de enfermedades parasitarias
MX2022011964A (es) Moduladores de mtorc1 y usos de los mismos.
BR112017025263A2 (pt) método para o tratamento de doença neurológica
CL2018002074A1 (es) Composiciones y métodos para tratar infecciones.
ECSP14013130A (es) N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina
CO2022014499A2 (es) Moduladores de nlrp3
EA201991488A1 (ru) Модуляторы калиевых каналов
AR107460A1 (es) Gabapentina oftálmica para el tratamiento de las úlceras corneales